ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

CIK: 0001845297 · Show all filings

Period: Q2 2021 (← Previous) (Next →)

Filing Date: Aug 16, 2021

Total Value ($000): $29,870 (100.0% shares, 0.0% debt)

Holdings (7)

AVIR ATEA PHARMACEUTICALS INC 91.0%

Value ($000) $27,186 Shares 1,265,631 Est. Cost $30.05 Unrealized 0.0%

GNCAQ GENOCEA BIOSCIENCES INC 2.9%

Value ($000) $878 Shares 375,000 Est. Cost $2.28 Unrealized +5.8%

— SYNLOGIC INC 2.7%

Value ($000) $801 Shares 205,906 Est. Cost $2.16 Unrealized —

— AERPIO PHARMACEUTICALS INC 2.3%

Value ($000) $676 Shares 400,000 Est. Cost $0.98 Unrealized —

LUNG PULMONX CORP 0.7%

Value ($000) $199 Shares 4,521 Est. Cost $48.97 Unrealized -11.1%

— IDERA PHARMACEUTICALS INC 0.2%

Value ($000) $68 Shares 56,250 Est. Cost $3.66 Unrealized —

— NABRIVA THERAPEUTICS PLC 0.2%

Value ($000) $62 Shares 45,849 Est. Cost $2.42 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
AVIR	ATEA PHARMACEUTICALS INC	1,265,631	$27,186	91.0%	$30.05	0.0%	COM	04683R106
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$878	2.9%	$2.28	+5.8%	COM NEW	372427401
—	SYNLOGIC INC	205,906	$801	2.7%	$2.16	—	COM	87166L100
—	AERPIO PHARMACEUTICALS INC	400,000	$676	2.3%	$0.98	—	COM	00810B105
LUNG	PULMONX CORP	4,521	$199	0.7%	$48.97	-11.1%	COM	745848101
—	IDERA PHARMACEUTICALS INC	56,250	$68	0.2%	$3.66	—	COM PAR	45168K405
—	NABRIVA THERAPEUTICS PLC	45,849	$62	0.2%	$2.42	—	SHS	G63637113